[1]
|
Torre, L.A., Siegel, R.L., Ward, E.M. and Jemal, A. (2016) Global Cancer Incidence and Mortality Rates and Trends—An Update. Cancer Epidemiology, Biomarkers & Prevention, 25, 16-27.
https://doi.org/10.1158/1055-9965.EPI-15-0578
|
[2]
|
Litwin, M.S. and Tan, H.J. (2017) The Diagnosis and Treat-ment of Prostate Cancer: A Review. JAMA, 317, 2532-2542.
https://doi.org/10.1001/jama.2017.7248
|
[3]
|
尤祥云, 孙德明, 喻俊峰, 易成, 向振东. 前列腺癌双极雄激素治疗的研究进展[J]. 临床泌尿外科杂志, 2021, 36(12): 989-992.
|
[4]
|
罗伟, 吴静, 方克伟. C-反应蛋白与前列腺癌相关性的研究进展[J]. 东南国防医药, 2020, 22(5): 516-520.
|
[5]
|
Lilja, H. (2008) Testing New PSA Subforms to Enhance the Accuracy of Predicting Cancer Risk and Disease Outcome in Prostate Cancer. Clinical Chemistry, 54, 1248-1249. https://doi.org/10.1373/clinchem.2007.101204
|
[6]
|
Lilja, H., Ulmert, D. and Vickers, A.J. (2008) Prostate-Specific Antigen and Prostate Cancer: Prediction, Detection and Monitoring. Nature Reviews Cancer, 8, 268-278. https://doi.org/10.1038/nrc2351
|
[7]
|
Cary, K.C. and Cooperberg, M.R. (2013) Biomarkers in Prostate Cancer Surveillance and Screening: Past, Present, and Future. Therapeutic Advances in Urology, 5, 318-329. https://doi.org/10.1177/1756287213495915
|
[8]
|
文锐, 马可为, 黄翔华, 乔建坤, 云志中. 前列腺癌早期诊断相关生物标志物的研究进展[J]. 内蒙古医学杂志, 2022, 54(7): 821-824+828.
|
[9]
|
Saini, S. (2016) PSA and Be-yond: Alternative Prostate Cancer Biomarkers. Cellular Oncology, 39, 97-106.
https://doi.org/10.1007/s13402-016-0268-6
|
[10]
|
Hart, P.C., Rajab, I.M., Alebraheem, M. and Potempa, L.A. (2020) C-Reactive Protein and Cancer-Diagnostic and Therapeutic Insights. Frontiers in Immunology, 11, Article ID: 595835. https://doi.org/10.3389/fimmu.2020.595835
|
[11]
|
Stikbakke, E., Richardsen, E., Knutsen, T., Wilsgaard, T., Gio-vannucci, E.L., McTiernan, A., Eggen, A.E., Haugnes, H.S. and Thune, I. (2020) Inflammatory Serum Markers and Risk and Severity of Prostate Cancer: The PROCA-Life Study. International Journal of Cancer, 147, 84-92. https://doi.org/10.1002/ijc.32718
|
[12]
|
De Nunzio, C., Kramer, G., Marberger, M., Montironi, R., Nelson, W., Schröder, F., Sciarra, A. and Tubaro, A. (2011) The Controversial Relationship between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation. European Urology, 60, 106-117. https://doi.org/10.1016/j.eururo.2011.03.055
|
[13]
|
Sciarra, A., Gentilucci, A., Salciccia, S., Pierella, F., Del Bianco, F., Gentile, V., Silvestri, I. and Cattarino, S. (2016) Prognostic Value of Inflammation in Prostate Cancer Progression and Response to Therapeutic: A Critical Review. Journal of Inflammation, 13, Article No. 35. https://doi.org/10.1186/s12950-016-0143-2
|
[14]
|
Ablij, H. and Meinders, A. (2002) C-Reactive Protein: History and Revival. European Journal of Internal Medicine, 13, 412-422. https://doi.org/10.1016/S0953-6205(02)00132-2
|
[15]
|
Moutachakkir, M., Lamrani Hanchi, A., Baraou, A., Bou-khira, A. and Chellak, S. (2017) Immunoanalytical Characteristics of C-Reactive Protein and High Sensitivity C-Reactive Protein. Annales de Biologie Clinique, 75, 225-229.
https://doi.org/10.1684/abc.2017.1232
|
[16]
|
Sevcenco, S., Mathieu, R., Baltzer, P., Klatte, T., Fajkovic, H., Seitz, C., Karakiewicz, P.I., Rouprêt, M., Rink, M., Kluth, L., Trinh, Q.D., Loidl, W., Briganti, A., Scherr, D.S. and Shariat, S.F. (2016) The Prognostic Role of Preoperative Serum C-Reactive Protein in Predicting the Biochemical Recurrence in Pa-tients Treated with Radical Prostatectomy. Prostate Cancer and Prostatic Diseases, 19, 163-167. https://doi.org/10.1038/pcan.2015.60
|
[17]
|
Hall, W.A., Nickleach, D.C., Master, V.A., Prabhu, R.S., Rossi, P.J., Godette, K., Cooper, S. and Jani, A.B. (2013) The Association between C-Reactive Protein (CRP) Level and Biochemical Failure-Free Survival in Patients after Radiation Therapy for Nonmetastatic Adenocarcinoma of the Prostate. Cancer, 119, 3272-3279.
https://doi.org/10.1002/cncr.28185
|
[18]
|
Van Hemelrijck, M., Jungner, I., Walldius, G., Garmo, H., Binda, E., Hayday, A., Lambe, M., Holmberg, L. and Hammar, N. (2011) Risk of Prostate Cancer Is Not Associated with Levels of C-Reactive Protein and Other Commonly Used Markers of Inflammation. International Journal of Cancer, 129, 1485-1492. https://doi.org/10.1002/ijc.25773
|
[19]
|
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B.Y.,Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., De Porre, P., Kheoh, T., Park, Y.C., Todd, M.B., Chi, K.N. and LATITUDE Investigators (2017) Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. New England Journal of Medicine, 377, 352-360. https://doi.org/10.1056/NEJMoa1704174
|
[20]
|
Davis, I.D., Martin, A.J., Stockler, M.R., Begbie, S., Chi, K.N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W.E., Horvath, L.G., Joshua, A.M., Lawrence, N.J., Marx, G., McCaffrey, J., McDermott, R., McJannett, M., North, S.A., Parnis, F., Parulekar, W., Pook, D.W., Reaume, M.N., Sandhu, S.K., Tan, A., Tan, T.H., Thomson, A., Tu, E., Vera-Badillo, F., Williams, S.G., Yip, S., Zhang, A.Y., Zielinski, R.R., Sweeney, C.J. and ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2019) Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. New England Journal of Medicine, 381, 121-131.
https://doi.org/10.1056/NEJMoa1903835
|
[21]
|
Fizazi, K., Shore, N., Tammela, T.L., Ulys, A., Vjaters, E., Polya-kov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., Kappeler, C., Snapir, A., Sarapohja, T., Smith, M.R. and ARAMIS Investigators (2019) Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. New England Journal of Medicine, 380, 1235-1246.
https://doi.org/10.1056/NEJMoa1815671
|
[22]
|
O’Brian, D., Prunty, M., Hill, A. and Shoag, J. (2021) The Role of C-Reactive Protein in Kidney, Bladder, and Prostate Cancers. Frontiers in Immunology, 12, Article ID: 721989. https://doi.org/10.3389/fimmu.2021.721989
|
[23]
|
胡志全, 甘家骅, 田继华. 转移性前列腺癌新型内分泌药物治疗进展[J]. 中华泌尿外科杂志, 2021, 42(Z2): 3-6.
|
[24]
|
McArdle, P.A., Mir, K., Almushatat, A.S., Wallace, A.M., Underwood, M.A. and McMillan, D.C. (2006) Systemic Inflammatory Response, Prostate-Specific Antigen and Survival in Patients with Metastatic Prostate Cancer. Urologia Internationalis, 77, 127-129. https://doi.org/10.1159/000093905
|
[25]
|
Nakashima, J., Kikuchi, E., Miyajima, A., Nakagawa, K., Oya, M., Ohi-gashi, T. and Murai, M. (2008) Simple Stratification of Survival Using Bone Scan and Serum C-Reactive Protein in Prostate Cancer Patients with Metastases. Urologia Internationalis, 80, 129-133. https://doi.org/10.1159/000112601
|
[26]
|
Liu, Y., Chen, J.Q., Xie, L., Wang, J., Li, T., He, Y., Gao, Y., Qin, X. and Li, S. (2014) Effect of Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs on Prostate Cancer Incidence and Mortality: A Systematic Review and Meta-Analysis. BMC Medicine, 12, Article No. 55. https://doi.org/10.1186/1741-7015-12-55
|